Dose-dependent effects of corticosteroids on the expression of matrix-related genes in normal and cytokine-treated articular chondrocytes

Inflammation Research

Volumn 52, Issue 1, 2003, Pages 39-49

  Richardson, D W ^a   Dodge, G R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Chondrocyte; Corticosteroid; Cytokine; Metalloproteinase

Indexed keywords

AGGRECAN; BIGLYCAN; COLLAGEN TYPE 2; COMPLEMENTARY DNA; CYTOKINE; DECORIN; DEXAMETHASONE; FERRITIN; FIBRONECTIN; GLUCOCORTICOID; LINK PROTEIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1BETA; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CARTILAGE MATRIX; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA PROBE; DRUG EFFECT; DRUG POTENCY; ENZYME DEGRADATION; FLUOROGRAPHY; GENE EXPRESSION REGULATION; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ADRENAL CORTEX HORMONES; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BONE MATRIX; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; CYTOKINES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRITINS; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HORSES; HUMANS; INTERLEUKIN-1; MATRIX METALLOPROTEINASES; PHENOTYPE; PREDNISOLONE; PROTEIN BIOSYNTHESIS; PROTEINS; RECOMBINANT PROTEINS; RNA, MESSENGER; TRIAMCINOLONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037280454     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110300012     Document Type: Article

References (83)

1. Caldwell JR. Intra-articular corticosteroids. Guide to selection and indications for use. Drugs 1996; 52: 507-14.
2. Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. Ann Rheum Dis 1996; 55: 829-32.
3. Gray RG, Gottlieb NL. Intra-articular corticosteroids. An updated assessment. Clin Orthop 1983: 235-63.
4. Creamer P. Intra-articular corticosteroid treatment in osteoarthritis. Curr Opin Rheum 1999; 11: 417-21.
5. Jolly WT, Whittem T, Jolly AC, Firth EC. The dose-related effects of phenylbutazone and a methylprednisolone acetate formulation (Depo-Medrol) on cultured explants of equine carpal articular cartilage. J Vet Pharmacol Ther 1995; 18: 429-37.
6. Silbermann M, von der Mark K, Maor G, van Menxel M. Dexamethasone impairs growth and collagen synthesis in condylar cartilage in vitro. Bone Miner 1987; 2: 87-106.
7. Tessler RH, Salmon WD, Jr. Glucocorticoid inhibition of sulfate incorporation by cartilage of normal rats. Endocrinology 1975; 96: 898-902.
8. Chunekamrai S, Krook LP, Lust G, Maylin GA. Changes in articular cartilage after intra-articular injections of methylprednisolone acetate in horses. Am J Vet Res 1989; 50: 1733-41.
9. Trotter GW, McIlwraith CW, Yovich JV, Norrdin RW, Wrigley RH, Lamar CH. Effects of intra-articular administration of methylprednisolone acetate on normal equine articular cartilage. Am J Vet Res 1991; 52: 83-7.
10. Shoemaker RS, Bertone AL, Martin GS, McIlwraith CW, Roberts ED, Pechman R et al. Effects of intra-articular administration of methylprednisolone acetate on normal articular cartilage and on healing of experimentally induced osteochondral defects in horses. Am J Vet Res 1992; 53: 1446-53.
11. Foland JW, McIlwraith CW, Trotter GW, Powers BE, Lamar CH. Effect of betamethasone and exercise on equine carpal joints with osteochondral fragments. Vet Surg 1994; 23: 369-76.
12. Carter BG, Bertone AL, Weisbrode SE, Bailey MQ, Andrews JM, Palmer JL. Influence of methylprednisolone acetate on osteochondral healing in exercised tarsocrural joints of horses. Am J Vet Res 1996; 57: 914-22.
13. Pelletier JP, Mineau F, Raynauld JP, Woessner JF Jr, Gunja-Smith Z, Martel-Pelletier J. Intraarticular injections with methylprednisolone acetate reduce osteoarthritic lesions in parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis. Arthritis Rheum 1994; 37: 414-23.
14. Pelletier JP, DiBattista JA, Raynauld JP, Wilhelm S, Martel-Pelletier J. The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1, and oncogene protein synthesis in experimental osteoarthritis. Lab Invest 1995; 72: 578-86.
15. Stricker SJ, Lozman PR, Makowski AL, Gunja-Smith Z. Chondroprotective effect of betamethasone in lapine pyogenic arthritis. J Pediatr Orthop 1996; 16: 231-6.
16. Oikarinen AI, Vuorio EI, Zaragoza EJ, Palotie A, Chu ML, Uitto J. Modulation of collagen metabolism by glucocorticoids. Receptor-mediated effects of dexamethasone on collagen biosynthesis in chick embryo fibroblasts and chondrocytes. Biochem Pharmacol 1988; 37: 1451-62.
17. Srinivas GR, Chichester CO, Barrach HJ, Matoney AL. Effects of certain antiarthritic agents on the synthesis of type II collagen and glycosaminoglycans in rat chondrosarcoma cultures. Agents Actions 1994; 41: 193-9.
18. Todhunter RJ, Fubini SL, Wootton JA, Lust G. Effect of methylprednisolone acetate on proteoglycan and collagen metabolism of articular cartilage explants. J Rheumatol 1996; 23: 1207-13.
19. Su S, Dehnade F, Zafarullah M. Regulation of tissue inhibitor of metalloproteinases-3 gene expression by transforming growth factor-beta and dexamethasone in bovine and human articular chondrocytes. DNA Cell Biol 1996; 15: 1039-48.
20. Caron JP, Tardif G, Martel-Pelletier J, DiBattista JA, Geng C, Pelletier JP. Modulation of matrix metalloprotease 13 (collagenase 3) gene expression in equine chondrocytes by interleukin 1 and corticosteroids. Am J Vet Res 1996; 57: 1631-4.
21. Fubini SL, Todhunter RJ, Burton-Wurster N, Vernier-Singer M, MacLeod JN. Corticosteroids alter the differentiated phenotype of articular chondrocytes. J Orthop Res 2001; 19: 688-95.
22. MacLeod JN, Fubini SL, Gu DN, Tetreault JW, Todhunter RJ. Effect of synovitis and corticosteroids on transcription of cartilage matrix proteins. Am J Vet Res 1998; 59: 1021-6.
23. Westacott CI, Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum 1996; 25: 254-72.
24. van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001; 30: 7-16.
25. Lotz M. Cytokines in cartilage injury and repair. Clin Orthop 2001(391 Suppl): S108-15.
26. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999; 40: 1-11.
27. Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001; 9: 539-52.
28. Richardson DW, Dodge GR. Effects of interleukin-1beta and tumor necrosis factor-alpha on expression of matrix-related genes by cultured equine articular chondrocytes. Am J Vet Res 2000; 61: 624-30.
29. Glade MJ, Kanwar YS, Hefley TJ. Enzymatic isolation of chondrocytes from immature rabbit articular cartilage and maintenance of phenotypic expression in culture. J Bone Miner Res 1991; 6: 217-226.
30. Estrada LE, Dodge GR, Richardson DW, Farole A, Jimenez SA. Characterization of a biomaterial with cartilage-like properties expressing type X collagen generated in vitro using neonatal porcine articular and growth plate chondrocytes. Osteoarthritis Cartilage 2001; 9: 169-177.
31. Reginato AM, Iozzo RV, Jimenez SA. Formation of nodular structures resembling mature articular cartilage in long-term primary cultures of human fetal epiphyseal chondrocytes on a hydrogel substrate. Arthritis Rheum 1994; 37: 1338-49.
32. Clegg PD, Coughlan AR, Riggs CM, Carter SD. Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine Vet J 1997; 29: 343-8.
33. Clegg PD, Burke RM, Coughlan AR, Riggs CM, Carter SD. Characterisation of equine matrix metalloproteinase 2 and 9; and identification of the cellular sources of these enzymes in joints. Equine Vet J 1997; 29: 33-42.
34. Kimoto S, Cheng SL, Zhang SF, Avioli LV. The effect of glucocorticoid on the synthesis of biglycan and decorin in human osteoblasts and bone marrow stromal cells. Endocrinology 1994; 135: 2423-31.
35. Kahari VM, Hakkinen L, Westermarck J, Larjava H. Differential regulation of decorin and biglycan gene expression by dexamethasone and retinoic acid in cultured human skin fibroblasts. J Invest Dermatol 1995; 104: 503-8.
36. Dodge GR, Diaz A, Sanz-Rodriguez C, Reginato AM, Jimenez SA. Effects of interferon-gamma and tumor necrosis factor alpha on the expression of the genes encoding aggrecan, biglycan, and decorin core proteins in cultured human chondrocytes. Arthritis Rheum 1998; 41: 274-83.
37. Roughley PJ, Lee ER. Cartilage proteoglycans: structure and potential functions. Microsc Res Tech 1994; 28: 385-97.
38. Hocking AM, Shinomura T, McQuillan DJ. Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 1998; 17: 1-19.
39. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, Goldstein S et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 1998; 20: 78-82.
40. Knudson CB, Knudson W. Cartilage proteoglycans. Semin Cell Dev Biol 2001; 12: 69-78.
41. Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, Hook M. Binding of the proteoglycan decorin to collagen type VI. J Biol Chem 1992; 267: 5250-6.
42. Little CB, Ghosh P, Bellenger CR. Topographic variation in biglycan and decorin synthesis by articular cartilage in the early stages of osteoarthritis: an experimental study in sheep. J Orthop Res 1996; 14: 433-44.
43. Dourado GS, Adams ME, Matyas JR, Huang D. Expression of biglycan, decorin and fibromodulin in the hypertrophic phase of experimental osteoarthritis. Osteoarthritis Cartilage 1996; 4: 187-96.
44. Roughley PJ, Melching LI, Recklies AD. Changes in the expression of decorin and biglycan in human articular cartilage with age and regulation by TGF-beta. Matrix Biol 1994; 14: 51-9.
45. Platt D, Bird JLE, Bayliss MT. Ageing of equine articular cartilage: structure and composition of aggrecan and decorin. Equine Vet J 1998; 30: 43-52.
46. Burton-Wurster N, Lust G. Fibronectin in Cartilage. In: Carsons S, editor. Fibronectin in Health and Disease. Boca Raton, FL: CRC Press; 1989. p. 243-254.
47. Burton-Wurster N, Lust G, Macleod JN. Cartilage fibronectin isoforms: in search of functions for a special population of matrix glycoproteins. Matrix Biol 1997; 15: 441-54.
48. Nimmer D, Bergtrom G, Hirano H, Amrani DL. Regulation of plasma fibronectin biosynthesis by glucocorticoids in chick hepatocyte cultures. J Biol Chem 1987; 262: 10369-75.
49. Dean DC, Newby RF, Bourgeois S. Regulation of fibronectin biosynthesis by dexamethasone, transforming growth factor beta, and cAMP in human cell lines. J Cell Biol 1988; 106: 2159-70.
50. Lust G, Burton-Wurster N, Leipold H. Fibronectin as a marker for osteoarthritis. J Rheumatol 1987; 14(Spec No): 28-9.
51. Barilla ML, Carsons SE. Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum 2000; 29: 252-65.
52. Homandberg GA. Cartilage damage by matrix degradation products: fibronectin fragments. Clin Orthop 2001 (391 Suppl): S100-7.
53. Neame PJ, Barry FP. The link proteins. EXS 1994; 70: 53-72.
54. Dudhia J, Platt D. Complete primary sequence of equine cartilage link protein deduced from complementary DNA. Am J Vet Res 1995; 56: 959-65.
55. Ratcliffe A, J. BP, F. S-N. Differential levels of synovial fluid aggrecan aggregate components in experimental osteoarthritis and joint disuse. J Orthop Res 1994; 12: 464-473.
56. Cs-Szabo G, Melching LI, Roughley PJ, Glant TT. Changes in messenger RNA and protein levels of proteoglycans and link protein in human osteoarthritic cartilage samples. Arthritis Rheum 1997; 40: 1037-45.
57. Bolton MC, Dudhia J, Bayliss MT. Quantification of aggrecan and link-protein mRNA in human articular cartilage of different ages by competitive reverse transcriptase-PCR. Biochem J 1996; 319: 489-98.
58. Rhodes C, Yamada Y. Characterization of a glucocorticoid responsive element and identification of an AT-rich element that regulate the link protein gene. Nucleic Acids Res 1995; 23: 2305-13.
59. Kwak EL, Larochelle DA, Beaumont C, Torti SV, Torti FM. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem 1995; 270: 15285-93.
60. Rogers JT, Bridges KR, Durmowicz GP, Glass J, Auron PE, Munro HN. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 1990; 265: 14572-8.
61. Rogers JT, Andriotakis JL, Lacroix L, Durmowicz GP, Kasschau KD, Bridges KR. Translational enhancement of H-ferritin mRNA by interleukin-1 beta acts through 5′ leader sequences distinct from the iron responsive element. Nucleic Acids Res 1994; 22: 2678-86.
62. Tsuji Y, Miller LL, Miller SC, Torti SV, Torti FM. Tumor necrosis factor-alpha and interleukin 1-alpha regulate transferrin receptor in human diploid fibroblasts. Relationship to the induction of ferritin heavy chain. J Biol Chem 1991; 266: 7257-61.
63. Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA 1997; 94: 2150-2155.
64. Ota T, Katsuki I. Ferritin subunits in sera and synovial fluids from patients with rheumatoid arthritis. J Rheumatol 1998; 25: 2315-8.
65. Kumon Y, Suehiro T, Nishiya K, Hashimoto K, Nakatani K, Sipe JD. Ferritin correlates with C-reactive protein and acute phase serum amyloid A in synovial fluid, but not in serum. Amyloid 1999; 6: 130-5.
66. Stuhlmuller B, Ungethum U, Scholze S, Martinez L, Backhaus M, Kraetsch HG et al. Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 775-90.
67. Morris EA, Treadwell BV. Effect of interleukin 1 on articular cartilage from young and aged horses and comparison with metabolism of osteoarthritic cartilage. Am J Vet Res 1994; 55: 138-46.
68. Richardson D, Dodge G. Molecular characteristics of equine stromelysin and tissue inhibitor of metalloproteinase 1. Am J Vet Res 1998; 59: 1557-62.
69. Balkman CE, Nixon AJ. Molecular cloning and cartilage gene expression of equine stromelysin 1 (matrix metalloproteinase 3). Am J Vet Res 1998; 59: 30-6.
70. Pelletier JP, McCollum R, DiBattista J, Loose LD, Cloutier JM, Martel-Pelletier J. Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum 1993; 36: 1517-27.
71. Fernandes JC, Martel-Pelletier J, Lascau-Coman V, Moldovan F, Jovanovic D, Raynauld JP et al. Collagenase-1 and collagenase-3 synthesis in normal and early experimental osteoarthritic canine cartilage: an immunohistochemical study. J Rheumatol 1998; 25: 1585-94.
72. Dean DD, Azzo W, Martel-Pelletier J, Pelletier JP, Woessner JF, Jr. Levels of metalloproteases and tissue inhibitor of metalloproteases in human osteoarthritic cartilage. J Rheumatol 1987; 14: 43-4.
73. Woessner JF, Jr., Gunja-Smith Z. Role of metalloproteinases in human osteoarthritis. J Rheumatol-Suppl 1991; 27: 99-101.
74. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier J-P. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994; 70: 807-15.
75. Pelletier JP, Mineau F, Faure MP, Martel-Pelletier J. Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis Rheum 1990; 33: 1466-76.
76. Pelletier JP, Martel-Pelletier J. Protective effects of corticosteroids on cartilage lesions and osteophyte formation in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum 1989; 32: 181-93.
77. Williams JM, Brandt KD. Triamcinolone hexacetonide protects against fibrillation and osteophyte formation following chemically induced articular cartilage damage. Arthritis Rheum 1985; 28: 1267-74.
78. Autefage A, Alvinerie M, Toutain PL. Synovial fluid and plasma kinetics of methylprednisolone and methylprednisolone acetate in horses following intra-articular administration of methylprednisolone acetate. Equine Vet J 1986; 18: 193-8.
79. Lillich JD, Bertone AL, Schmall LM, Ruggles AJ, Sams RA. Plasma, urine, and synovial fluid disposition of methylprednisolone acetate and isoflupredone acetate after intra-articular administration in horses. Am J Vet Res 1996; 57: 187-92.
80. Edwards DR, Rocheleau H, Sharma RR, Wills AJ, Cowie A, Hassell JA et al. Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochim Biophys Acta 1992; 1171: 41-55.
81. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 1996; 6: 391-411.
82. Borden P, Heller RA. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr 1997; 7: 159-78.
83. Krebsbach PH, Nakata K, Bernier SM, Hatano O, Miyashita T, Rhodes CS et al. Identification of a minimum enhancer sequence for the type II collagen gene reveals several core sequence motifs in common with the link protein gene. J Biol Chem 1996; 271: 4298-303.